Form 4: Cadrenal CFO Sells Shares Under 10b5-1 Plan

Cadrenal Therapeutics' CFO, Matthew K. Szot, reported the sale of common stock totaling 3,493 shares through a pre-arranged 10b5-1 trading plan.

Summary

• Matthew K. Szot, Chief Financial Officer of Cadrenal Therapeutics, Inc. (CVKD), reported two transactions involving the sale of common stock.
• On October 9, 2025, Mr. Szot sold 1,693 shares of common stock at a price of $13.99 per share.
• On October 13, 2025, an additional 1,800 shares of common stock were sold at a price of $14.07 per share.
• Following these transactions, Mr. Szot beneficially owns 13,533 shares of Cadrenal Therapeutics common stock.
• All reported sales were conducted in accordance with a Rule 10b5-1 trading arrangement.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of insider stock sales executed under a pre-arranged 10b5-1 trading plan, which is a standard practice for corporate officers and does not inherently indicate positive or negative company performance.

Positives

• The sales were executed under a Rule 10b5-1 trading arrangement, indicating a pre-planned divestment strategy rather than opportunistic trading.

Negatives

• A reduction in direct ownership by a key executive, such as the Chief Financial Officer, could be perceived negatively by some investors.

Industry Context

This filing is a routine disclosure of an insider transaction and does not provide broader industry context or trends. Insider trading activity is a common aspect of public markets, with Rule 10b5-1 plans often used by executives for personal financial planning while adhering to insider trading regulations.

Stakeholder Impact

• Shareholders may observe a reduction in the Chief Financial Officer's direct equity stake, which could be interpreted in various ways, though the 10b5-1 plan suggests a pre-determined sale.

Key Dates

Recommendation

The filing reports routine insider sales by the CFO under a pre-arranged 10b5-1 plan. While insider selling can sometimes be viewed negatively, the pre-planned nature mitigates immediate concerns. This event alone does not provide sufficient information to alter a fundamental investment thesis, thus a 'hold' recommendation is appropriate pending further company-specific or market developments.

Keywords

Cadrenal Therapeutics, CVKD, Matthew K. Szot, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, CFO